ASAN FOUNDATION
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1989-06-23
- Employees
- 501
- Market Cap
- -
- Website
- https://ails.amc.seoul.kr
Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Phase 2
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- Drug: Rituximab+mVPDL
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 78
- Registration Number
- NCT01429610
- Locations
- 🇰🇷
Division of Hematology-Oncology, Dong-A University College of Medicine, Busan, Korea, Republic of
🇰🇷Hematologic Oncology Clinic, National Cancer Center, Ilsan, Kongki, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2011-09-09
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 1000
- Registration Number
- NCT01428752
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum
Phase 2
Completed
- Conditions
- Bladder CancerUreter Cancer
- Interventions
- Drug: Genexol PM
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2011-12-07
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT01426126
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Early Percutaneous Mitral Intervention in Asymptomatic Moderate Mitral Stenosis
Not Applicable
Completed
- Conditions
- Moderate Mitral Stenosis
- Interventions
- Procedure: Percutaneous Mitral Commissurotomy
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 167
- Registration Number
- NCT01406353
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Yonsei University Severance Hospital, Seoul, Korea, Republic of
Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer
Phase 2
Withdrawn
- Conditions
- ThyroidCancer
- Interventions
- Drug: alpha-lipoic acids
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Asan Medical Center
- Registration Number
- NCT01396733
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
Phase 2
Completed
- Conditions
- Her-2 Positive Gastric CancerMetastatic or Recurrent Gastric Adenocarcinoma
- Interventions
- Drug: Herceptin+XELOX
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT01396707
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Development of a Prediction Model for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease
Completed
- Conditions
- Intestinal TuberculosisCrohn's Disease
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 117
- Registration Number
- NCT01392365
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in Healthy Male Volunteers Under Fed Condition
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT01383330
Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma
Phase 2
Completed
- Conditions
- Metastatic Biliary Cancer
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 92
- Registration Number
- NCT01375972
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers
Phase 1
- Conditions
- Atazanavir
- Interventions
- Drug: Atazanavir(ATZ) and Tenofovir(TDF)Drug: atazanavir(ATZ) + tenofovir(TDF) + ritonavir
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT01368783
- Locations
- 🇰🇷
Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath